NTLA Intellia Therapeutics, Inc.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1652130 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-8.1%
TTM net income YoY4.4%
TTM EPS YoY21.2%
Revenue 3-yr CAGR77.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-821.2%
Net margin-805.7%
FCF margin-677.1%
EBITDA margin-805.0%
Returns
ROE-62.6%
ROA-46.6%
ROIC (approx.)-63.2%
Asset turnover0.06x
Leverage & solvency
Liabilities / assets32.1%
Debt / equity0.12x
Current ratio6.31x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-7.8%
Payout ratio—
Capex / revenue5.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $7.16M | $7.66M | $15.05M | $23.02M | $13.78M | $14.24M | $16.63M | $12.87M |
| R&D expense | $83.35M | $82.59M | $80.74M | $88.65M | $94.75M | $97.03M | $108.43M | $116.88M |
| SG&A expense | $46.14M | $37.82M | $34.84M | $33.08M | $30.51M | $27.21M | $29.01M | $32.44M |
| Operating income | -$122.33M | -$112.76M | -$100.53M | -$98.71M | -$111.48M | -$110.00M | -$120.81M | -$136.45M |
| Interest expense | $611,000 | — | — | — | $0 | — | — | — |
| Net income | -$127.48M | -$106.63M | -$96.23M | -$95.79M | -$101.32M | -$101.25M | -$114.33M | -$128.90M |
| EBITDA | -$120.42M | -$110.66M | -$98.33M | -$96.33M | -$109.08M | -$107.50M | -$118.31M | -$133.88M |
| EPS (basic) | -0.91 | -0.80 | -0.81 | — | -0.92 | -0.98 | -1.10 | — |
| EPS (diluted) | -0.91 | -0.80 | -0.81 | — | -0.92 | -0.98 | -1.10 | — |
| Weighted avg. shares (diluted) | 140.19M | 133.48M | 118.49M | — | 110.19M | 103.73M | 103.50M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $156.10M | $106.13M | $134.70M | $155.46M | $193.39M | $156.17M | $126.88M | $189.18M |
| Short-term investments | $318.01M | $331.63M | $241.29M | $294.42M | $317.65M | $303.48M | $376.87M | $412.33M |
| Receivables | $7.50M | $7.32M | $9.13M | $9.47M | $11.05M | $11.35M | $10.50M | $8.52M |
| Current assets | $506.35M | $527.83M | $466.45M | $527.71M | $581.94M | $495.94M | $551.39M | $639.86M |
| PP&E, net | $13.92M | $15.06M | $15.52M | $17.67M | $20.42M | $22.81M | $25.12M | $27.38M |
| Total assets | $902.56M | $857.16M | $758.78M | $842.13M | $925.27M | $898.89M | $986.16M | $1.19B |
| Current liabilities | $80.31M | $79.39M | $76.44M | $103.88M | $93.73M | $95.50M | $112.59M | $110.85M |
| Long-term debt | $73.73M | — | — | $0 | — | — | — | — |
| Total debt | $73.73M | — | — | $0 | — | — | — | — |
| Total liabilities | $289.47M | $129.46M | $137.84M | $170.73M | $176.85M | $183.64M | $206.24M | $319.06M |
| Shareholders' equity | $613.09M | $727.71M | $620.94M | $671.39M | $748.42M | $715.25M | $779.92M | $871.96M |
| Net debt | -$82.37M | — | — | -$155.46M | — | — | — | — |
| Shares outstanding | 140.25M | 140.02M | 120.45M | 116.32M | 115.79M | 105.33M | 103.54M | 102.03M |
| Cash flow statement | ||||||||
| Operating cash flow | -$85.43M | -$83.11M | -$117.35M | -$69.28M | -$76.90M | -$99.62M | -$148.93M | -$85.19M |
| Capital expenditure | $888,000 | $1.81M | $79,000 | $126,000 | $29,000 | $239,000 | $735,000 | $981,000 |
| Free cash flow | -$86.32M | -$84.92M | -$117.42M | -$69.41M | -$76.93M | -$99.86M | -$149.66M | -$86.18M |
| Investing cash flow | $61.94M | -$141.57M | $66.31M | $27.53M | -$741,000 | $106.91M | $94.33M | $151.56M |
| Financing cash flow | $73.46M | $196.12M | $33.57M | $1.98M | $114.86M | $14.65M | $0 | $2.32M |
| Depreciation & amortization | $1.90M | $2.10M | $2.20M | $2.38M | $2.40M | $2.50M | $2.50M | $2.57M |
| Stock-based compensation | $14.40M | $18.07M | $13.48M | $16.74M | $19.60M | $22.04M | $21.84M | $39.62M |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.